The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
GeyerC.E., ForsterJ.M., LindquistD.Lapatinib plus capecitabine for HER2-positive advanced breast cancer. J Clin Oncol.2006; 355(26): 2733–2743.
2.
CapriG., ChangJ., ChenS.C.An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol.2010; 21(3): 474–480.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
7.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines. Antiemesis. v.2.2010. NCCN Web site. http://www.nccn.org. Accessed July 19, 2010.
8.
Kris MG, Hesketh PJ, Somerfield MR, et al.American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
11.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
12.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
13.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexa-methasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19: 85(8): 1099–1101.
14.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
15.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety.2001; 24(10): 767–779.
18.
SmithT.J., KhatcheressianJ., LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
MarounJ.A., AnthonyL.B., BlaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
21.
BensonA.B., AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
22.
GressettS.M., StanfordB.L., HardwickeF.Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Tract.2006; 12(3): 131–141.
